Transcode Therapeutics, INC. (RNAZ) — DEF 14A Filings
All DEF 14A filings from Transcode Therapeutics, INC.. Browse 5 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (5)
-
Transcode Therapeutics Seeks Shareholder Approval for Director Elections, Expanded Stock Plan
— Jul 15, 2025 Risk: medium
Transcode Therapeutics, Inc. (RNAZ) is holding its 2025 Annual Meeting on August 29, 2025, to address several key proposals. The company plans to elect four dir -
TransCode Therapeutics Files Definitive Proxy Statement
— Apr 11, 2025 Risk: low
TransCode Therapeutics, Inc. filed its definitive proxy statement on April 11, 2025, for its annual meeting of stockholders. The filing outlines the proposals t -
Transcode Therapeutics Files Definitive Proxy Statement
— Dec 30, 2024 Risk: low
Transcode Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on December 30, 2024, for its annual meeting of stockholders. The filing outlines th -
TransCode Therapeutics Files Proxy Statement for Annual Meeting
— Oct 28, 2024 Risk: low
TransCode Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on October 28, 2024, for its annual meeting of stockholders on November 22, 2024. The -
Transcode Therapeutics Announces 2024 Annual Meeting of Stockholders
— Apr 29, 2024 Risk: low
Transcode Therapeutics, Inc. (RNAZ) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Transcode Ther
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX